North America Ocular Pain Market, By Disease Type (Ocular Pain with Eye Diseases and Ocular Pain without Primary Eye Diseases), Type (Diagnosis and Treatment), Application (Conjunctivitis, Corneal Abrasion, Blepharitis, Sty, Iritis, Sinusitis, Migraines, Glaucoma, and Others), Route of Administration (Topical, Periocular, Intraocular, Oral and Others), Drug Type (Prescription and Over the Counter), Population Type (Adults and Geriatric), End User (Hospitals, Specialty Clinics, Home Healthcare Settings, Ophthalmology Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, Mexico.) – Industry Trends and Forecast to 2028.
Market Analysis and Insights : North America Ocular Pain Market
The North America ocular pain market is expected to grow in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.7% in the forecast period of 2021 to 2028 and is expected to reach USD 699.19 million by 2028. Increasing unhygienic and sedentary lifestyle acts as a driver for the North America ocular pain market growth.
Ocular pain also, known as eye pain, commonly occurs due to mild irritation, but it is rarely a symptom of a serious condition. Mostly the pain resolves without medicine or further treatment, and it recovers by the self-immune system. However, ocular pain with underlying primary ophthalmic disorders requires timely treatment. Eye pains are generally categorized under two categories, such as ocular pain, which occurs over the eye's surface, creating sensations of scratching, burning, or itching. They are caused due to a person’s eyelashes, foreign objects, infection, or trauma. Often ocular pain is treated with eye drops and topical steroids or NSAIDs. Ocular pain occurs with underlying primary eye diseases like conjunctivitis, contact lens irritation, corneal abrasion, injury, blepharitis, and sty. The other advanced treatments, like stimulation therapies, are also used for severe neuro ocular pain, appropriately diagnosed.
Increasing unhygienic and sedentary lifestyles, rising prevalence of ophthalmic disorders, and ocular pain act as drivers for the North America ocular pain market. The increasing awareness among people for eye-related diseases and growing cases of ocular migraine is further boosting the market growth. The side effects of eye treatment medicines and the high cost of eye treatment and medication are restraining the North America ocular pain market growth. Increasing research and development activities, rising healthcare expenditure and disposable income, and growing geriatric population acts as opportunities for the North America ocular pain market. Lack of healthcare facilities for eye treatment and stringent regulatory framework poses a challenge for the North America ocular pain market growth.
North America ocular pain market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the ocular pain market scenario, contact Data Bridge Market Research for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.
North America Ocular Pain Market Scope and Market Size
North America ocular pain market is segmented on the basis of the disease type, type, applications, route of administration, drug type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the North America ocular pain market is segmented into ocular pain with eye diseases and ocular pain without primary eye diseases. In 2021, the ocular pain with eye diseases segment is expected to dominate the North America ocular pain market as ocular pain is the initial symptom of most eye diseases.
- On the basis of type, the North America ocular pain market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market due to raising funds for research activities over diagnostic ophthalmology.
- On the basis of application, the North America ocular pain market is segmented into conjunctivitis, corneal abrasion, blepharitis, sty, iritis, sinusitis, migraines, glaucoma, and others. In 2021, the glaucoma segment is expected to dominate dominating the market due to less awareness during the initial stages of pain.
- On the basis of route of administration, the North America ocular pain market is segmented into topical, periocular, intraocular, oral, and others. In 2021, the topical segment is expected to dominate dominating the market as enormous topical solutions and products are implemented for ocular care.
- On the basis of drug type, the North America ocular pain market is segmented into prescription and over the counter. In 2021, the prescription segment is expected to dominate dominating the market due to rising government regulations and guidelines for OTC drugs, and hence prescription is mandated.
- On the basis of population type, the North America ocular pain market is segmented into adults and geriatric. In 2021, the adults segment is expected to dominate dominating the market due to their rising sedentary lifestyle and habits.
- On the basis of end user, the North America ocular pain market is segmented into hospitals, specialty clinics, home healthcare, ophthalmology centers, ambulatory surgical centers, and others. In 2021, the hospitals segment is expected to dominate dominating the market as there are increasing hospitals in developed countries of North America due to high economic growth.
- On the basis of distribution channel, the North America ocular pain market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2021, the direct tender segment is expected to dominate the market as they provide quality products.
North America Ocular Pain Market Country Level Analysis
North America ocular pain market is analyzed, and market size information is provided by the country, disease type, type, applications, route of administration, drug type, population type, end user, and distribution channel as referenced above.
The countries covered in the North America ocular pain market report are the U.S., Canada, and Mexico.
The diagnosis segment in the U.S of North American region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increasing cases of ophthalmic disorders. The diagnosis segment in Canada is the second dominating market in North America owing to the increasing unhygienic habits of people. Mexico is the third leading market in this region, and the diagnosis segment dominates in this country due to the rising number of market players and initiatives.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Ocular Pain Treatment is Boosting the Market Growth of the North America Ocular Pain Market
The North America ocular pain market also provides you with a detailed market analysis for every country's growth in a particular market. Additionally, it provides detailed information regarding the market players’ strategy and their geographical presence. The data is available for the historical period 2010 to 2019.
Competitive Landscape and North America Ocular Pain Market Share Analysis
The North America ocular pain market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the North America ocular pain market.
The major companies dealing in the North America ocular pain market are Johnson & Johnson Services, Inc., Pfizer Inc., EyePoint Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Akorn Operating Company LLC, AERIE PHARMACEUTICALS, INC., Sun Pharmaceutical Industries Ltd, Bausch & Lomb Incorporated, Ocular Therapeutix, Inc., Kala Pharmaceuticals, Novartis AG, Omeros Corporation, Allergan (An AbbVie Company), SiteOne Therapeutics, Inc., OKYO Pharma Limited, Fera Pharmaceuticals, Vyluma, TALLC Inc., IACTA Pharmaceuticals, Inc., Allakos Inc., Aldeyra Therapeutics, Inc., Novaliq GmbH, and among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contracts and agreements are also initiated by companies worldwide, which accelerate the North America ocular pain market.
For instance,
- In November 2020, Allakos Inc. participated in the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting. The company presented its product over Eosinophilic Gastrointestinal Diseases and other diseases to attended customers. This strengthened their position in the market
- In October 2020, Aldeyra Therapeutics, Inc. presented their Reproxalap ophthalmic solution’s (0.25% and 0.5%) clinical data, which surpassed phase 2. They also demonstrated their application over allergic conjunctivitis. This strengthened their position in a focused market
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player enhance the company's footprints in the ocular pain market, which also benefits the organization’s profit growth.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA OCULAR PAIN MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISEASE TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
4.3 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT OPTIONS
4.4 VOLUME OF PRESCRIPTION
5 PIPELINE ANALYSIS
6 REGIONAL SUMMARY
6.1 NORTH AMERICA
6.2 EUROPE
6.3 ASIA-PACIFIC
6.4 SOUTH AMERICA
6.5 THE MIDDLE EAST AND AFRICA
7 NORTH AMERICA OCULAR PAIN MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE
8.1.2 RISING PREVALENCE OF OPHTHALMIC DISORDERS AND OCULAR PAINS
8.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES
8.1.4 GROWING CASES OF OCULAR MIGRAINE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF EYE TREATMENT MEDICINES
8.2.2 HIGH COST OF EYE TREATMENT AND MEDICATION
8.3 OPPORTUNITIES
8.3.1 RISING HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
8.3.3 INCREASING GERIATRIC POPULATION
8.4 CHALLENGES
8.4.1 STRINGENT RULES & REGULATIONS
8.4.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT
9 IMPACT OF COVID-19 PANDEMIC ON THE NORTH AMERICA OCULAR PAIN MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 OCULAR PAIN WITH EYE DISEASES
10.2.1 OCULAR PAIN WITH RED EYE
10.2.2 OCULAR PAIN WITHOUT RED EYE
10.3 OCULAR PAIN WITHOUT PRIMARY EYE DISEASES
10.3.1 OCULAR MIGRAINE
10.3.2 GIANT CELL ARTERITIS
10.3.3 TRIGEMINAL NEURALGIAS
10.3.4 CAVERNOUS SINUS AND SUPERIOR FISSURE PROCESSES
10.3.5 CAROTID ARTERY DISSECTION
10.3.6 CAROTIDYNIA
10.3.7 OTHERS
11 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE
11.1 OVERVIEW
11.2 DIAGNOSIS
11.2.1 SENSORY TESTING
11.2.1.1 HAND LIGHT EXAMINATION
11.2.1.2 DIRECT OPHTHALMOSCOPIC EXAMINATIONS
11.2.1.3 SLIT LAMP EXAMINATION
11.2.1.4 FLUORESCEIN EXAMINATION
11.2.2 IMAGING TEST
11.2.2.1 CONFOCAL MICROSCOPY
11.2.2.2 FUNCTIONAL MRI
11.3 TREATMENT
11.3.1 LOCAL TREATMENT
11.3.1.1 TOPICAL STEROID
11.3.1.1.1 LOTEPREDNOL
11.3.1.1.2 DEXAMETHASONE
11.3.1.1.3 PREDNISOLONE
11.3.1.1.4 FLUOROMETHOLONE
11.3.1.1.5 OTHERS
11.3.1.2 NONSTEROIDAL ANTI-INFLAMMATORY (NSAID)
11.3.1.2.1 BROMFENAC
11.3.1.2.2 KETOROLAC
11.3.1.2.3 NEPAFENAC
11.3.1.2.4 DICLOFENAC
11.3.1.2.5 OTHERS
11.3.1.3 OTHERS
11.3.2 STIMULATION THERAPIES
11.3.2.1 DEEP BRAIN STIMULATION
11.3.2.2 TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS)
11.3.2.3 REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS)
11.3.2.4 SCRAMBLER THERAPY
11.3.2.5 OTHERS
11.3.3 OTHERS
12 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 GLAUCOMA
12.3 BLEPHARITIS
12.4 CONJUNCTIVITIS
12.5 CORNEAL ABRASION
12.6 STY
12.7 IRITIS
12.8 SINUSITIS
12.9 MIGRAINES
12.1 OTHERS
13 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 TOPICAL
13.2.1 SOLUTION
13.2.2 GELS
13.2.3 OINTMENTS
13.2.4 OTHERS
13.3 INTRAOCULAR
13.3.1 INTRAVITREAL
13.3.2 INTRACAMERAL
13.4 PERIOCULAR
13.4.1 SUBCONJUNCTIVAL
13.4.2 SUBTENON
13.4.3 PERIBULBAR
13.4.4 RETROBULBAR
13.5 ORAL
13.5.1 TABLETS
13.5.2 CAPSULE
13.5.3 OTHERS
13.6 OTHERS
14 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE
14.1 OVERVIEW
14.2 PRESCRIPTION
14.3 OVER THE COUNTER
15 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE
15.1 OVERVIEW
15.2 ADULTS
15.3 GERIATRIC
16 NORTH AMERICA OCULAR PAIN MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CLINICS
16.4 HOME HEALTHCARE
16.5 OPHTHALMOLOGY CENTERS
16.6 AMBULATORY SURGICAL CENTERS
16.7 OTHERS
17 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 HOSPITAL PHARMACY
17.4 RETAIL PHARMACY
17.5 ONLINE PHARMACY
17.6 OTHERS
18 NORTH AMERICA OCULAR PAIN MARKET, BY GEOGRAPHY
18.1 NORTH AMERICA
18.1.1 U.S.
18.1.2 CANADA
18.1.3 MEXICO
19 NORTH AMERICA OCULAR PAIN MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
20 SWOT ANALYSIS
21 COMPANY PROFILE
21.1 BAUSCH & LOMB INCORPORATED
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 NOVARTIS AG
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 OMEROS CORPORATION
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENTS
21.5 AKORN OPERATING COMPANY LLC
21.5.1 COMPANY SNAPSHOT
21.5.2 COMPANY SHARE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENTS
21.6 AERIE PHARMACEUTICALS, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ALDEYRA THERAPEUTICS, INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 PRODUCT PORTFOLIO
21.7.3 RECENT DEVELOPMENTS
21.8 ALLAKOS INC.
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENT
21.9 ALLERGAN (AN ABBVIE COMPANY)
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENTS
21.1 EYEPOINT PHARMACEUTICALS, INC.
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 FERA PHARMACEUTICALS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENTS
21.12 FORMOSAPHARMA PHARMACEUTICAL INC.
21.12.1 COMPANY SNAPSHOT
21.12.2 PRODUCT PORTFOLIO
21.12.3 RECENT DEVELOPMENT
21.13 IACTA PHARMACEUTICALS, INC.
21.13.1 COMPANY SNAPSHOT
21.13.2 PRODUCT PORTFOLIO
21.13.3 RECENT DEVELOPMENTS
21.14 JOHNSON & JOHNSON SERVICES, INC.
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 KALA PHARMACEUTICALS
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 NOVALIQ GMBH
21.17.1 COMPANY SNAPSHOT
21.17.2 PRODUCT PORTFOLIO
21.17.3 RECENT DEVELOPMENTS
21.18 OCULAR THERAPEUTIX, INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 OKYO PHARMA LIMITED
21.19.1 COMPANY SNAPSHOT
21.19.2 PRODUCT PORTFOLIO
21.19.3 RECENT DEVELOPMENTS
21.2 PFIZER, INC.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 PHARMALEADS SA
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENT
21.22 SITEONE THERAPEUTICS, INC.
21.22.1 COMPANY SNAPSHOT
21.22.2 PRODUCT PORTFOLIO
21.22.3 RECENT DEVELOPMENT
21.23 SYLENTIS
21.23.1 COMPANY SNAPSHOT
21.23.2 PRODUCT PORTFOLIO
21.23.3 RECENT DEVELOPMENT
21.24 TALLC INC.
21.24.1 COMPANY SNAPSHOT
21.24.2 PRODUCT PORTFOLIO
21.24.3 RECENT DEVELOPMENT
21.25 TARSIER PHARMA LTD.
21.25.1 COMPANY SNAPSHOT
21.25.2 PRODUCT PORTFOLIO
21.25.3 RECENT DEVELOPMENT
21.26 VYLUMA
21.26.1 COMPANY SNAPSHOT
21.26.2 PRODUCT PORTFOLIO
21.26.3 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
List of Table
TABLE 1 AVERAGE PRICING ANALYSIS OF VARIOUS TREATMENT PRODUCTS
TABLE 2 VOLUME OF PRESCRIPTION (%)
TABLE 3 NORTH AMERICA OCULAR PAIN MARKET, PIPELINE ANALYSIS
TABLE 4 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA GLAUCOMA IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA BLEPHARITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA CONJUNCTIVITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA CORNEAL ABRASION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA STY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA IRITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA SINUSITIS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA MIGRAINES IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA PRESCRIPTION IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA OVER THE COUNTER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA ADULTS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA GERIATRIC IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA HOSPITALS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA SPECIALTY CLINICS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA HOME HEALTHCARE IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA OPHTHALMOLOGY CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA DIRECT TENDER IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA HOSPITAL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA RETAIL PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA ONLINE PHARMACY IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA OTHERS IN OCULAR PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA OCULAR PAIN MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 63 NORTH AMERICA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 NORTH AMERICA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 NORTH AMERICA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 NORTH AMERICA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 NORTH AMERICA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 NORTH AMERICA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 71 NORTH AMERICA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 NORTH AMERICA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 NORTH AMERICA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 74 NORTH AMERICA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 75 NORTH AMERICA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 76 NORTH AMERICA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 77 NORTH AMERICA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 NORTH AMERICA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 79 NORTH AMERICA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 80 NORTH AMERICA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 NORTH AMERICA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 82 U.S. OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 83 U.S. OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 84 U.S. OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 85 U.S. OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 U.S. DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 U.S. SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 U.S. IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 U.S. TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 U.S. LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 U.S. TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 U.S. NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 U.S. STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 U.S. OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 95 U.S. OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 U.S. TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 U.S. INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 98 U.S. PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 99 U.S. ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 100 U.S. OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 101 U.S. OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 102 U.S. OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 103 U.S. OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 104 CANADA OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 105 CANADA OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 106 CANADA OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 107 CANADA OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 CANADA DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 CANADA SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 CANADA IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 CANADA TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 CANADA LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 CANADA TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 CANADA NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 CANADA STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 CANADA OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 117 CANADA OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 118 CANADA TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 119 CANADA INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 CANADA PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 121 CANADA ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 122 CANADA OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 123 CANADA OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 124 CANADA OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 CANADA OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 126 MEXICO OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 127 MEXICO OCULAR PAIN WITH EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 128 MEXICO OCULAR PAIN WITHOUT PRIMARY EYE DISEASES IN OCULAR PAIN MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 129 MEXICO OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 MEXICO DIAGNOSIS IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 MEXICO SENSORY TESTING IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 MEXICO IMAGING TEST IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 MEXICO TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 MEXICO LOCAL TREATMENT IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 MEXICO TOPICAL STEROID IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 136 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY (NSAID) IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 MEXICO STIMULATION THERAPIES IN OCULAR PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 MEXICO OCULAR PAIN MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 139 MEXICO OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 140 MEXICO TOPICAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 141 MEXICO INTRAOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 142 MEXICO PERIOCULAR IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 143 MEXICO ORAL IN OCULAR PAIN MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 144 MEXICO OCULAR PAIN MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 145 MEXICO OCULAR PAIN MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 146 MEXICO OCULAR PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 147 MEXICO OCULAR PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA OCULAR PAIN MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA OCULAR PAIN MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA OCULAR PAIN MARKET: NORTH AMERICA VS REGIONAL ANALYSIS
FIGURE 5 NORTH AMERICA OCULAR PAIN MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA OCULAR PAIN MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA OCULAR PAIN MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA OCULAR PAIN MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA OCULAR PAIN MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA OCULAR PAIN MARKET: SEGMENTATION
FIGURE 11 INCREASING UNHYGIENIC AND SEDENTARY LIFESTYLE IS EXPECTED TO DRIVE THE NORTH AMERICA OCULAR PAIN MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 OCULAR PAIN WITH EYE DISEASE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA OCULAR PAIN MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA OCULAR PAIN MARKET, AND ASIA-PACIFIC IS PROJECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA OCULAR PAIN MARKET
FIGURE 15 AGEING POPULATION IN THE WORLD (IN MILLIONS)
FIGURE 16 NORTH AMERICA AGEING POPULATION (IN MILLION)
FIGURE 17 EUROPE AGEING POPULATION (IN MILLION)
FIGURE 18 ASIA-PACIFIC AGEING POPULATION (IN MILLION)
FIGURE 19 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, 2020
FIGURE 20 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 23 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, 2020
FIGURE 24 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 26 NORTH AMERICA OCULAR PAIN MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, 2020
FIGURE 28 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, 2019-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 30 NORTH AMERICA OCULAR PAIN MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 NORTH AMERICA OCULAR PAIN MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, 2020
FIGURE 36 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 38 NORTH AMERICA OCULAR PAIN MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 39 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, 2020
FIGURE 40 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, 2019-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, CAGR (2021-2028)
FIGURE 42 NORTH AMERICA OCULAR PAIN MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 43 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, 2020
FIGURE 44 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 45 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, CAGR (2021-2028)
FIGURE 46 NORTH AMERICA OCULAR PAIN MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 48 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 49 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 50 NORTH AMERICA OCULAR PAIN MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 NORTH AMERICA OCULAR PAIN MARKET: SNAPSHOT (2020)
FIGURE 52 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2020)
FIGURE 53 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2021 & 2028)
FIGURE 54 NORTH AMERICA OCULAR PAIN MARKET: BY COUNTRY (2020 & 2028)
FIGURE 55 NORTH AMERICA OCULAR PAIN MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 56 NORTH AMERICA OCULAR PAIN MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
